Localized epithelioid peritoneal mesothelioma (LEPM) is a rare variant of peritoneal mesothelioma that presents as a solitary, circumscribed mass rather than with the diffuse serosal spread that characterizes the far more common diffuse form. Because it may arise in the pelvis and be accompanied by … More
Main Navigation Menu
➤ Asbestos Information Overview
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Mesothelioma, Asbestos Cancers, and Asbestos Diseases
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Some Information Concerning Our Law Firm
➤ A Brief Message from Attorney Tom Lamb
➤ Recent News & Reports: Asbestos / Mesothelioma
➤ Questions Clients Have Asked Us (FAQs)
➤ Sitemap for Asbestos-Mesothelioma.com
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Reports
A Rare Case of Pleural Deciduoid Mesothelioma With Histological, Immunohistochemical, Fluorescent In Situ Hybridization, and Ultrastructural Findings
Abstract: Owing to the rarity of deciduoid mesotheliomas, few studies have reported detailed morphological analyses. Here, we report a case of deciduoid mesothelioma along with cytological, histological, immunohistochemical, fluorescent in situ hybridization (FISH), and electron microscopic … More
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are … More
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median … More
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Background: [Keytruda and Lenvima (Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor))] showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate … More
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy
Pericardial mesothelioma (PM) is an extremely rare tumour for which only case reports, small case series, and case reviews have been published. This is a large population-based study on PM in Italy using data from the Italian National Mesothelioma Registry (Registro Nazionale Mesoteliomi, ReNaM). … More